Fusion Antibodies PLC 2019 AR2
The report outlines Fusion Antibodies plc's financial and operational performance for the fiscal year ended March 31, 2019. Despite a challenging first half, the company achieved record revenues in the second half, driven by its humanisation services and the introduction of the Rational Affinity Maturation Platform (RAMP™). Fusion Antibodies completed its laboratory capacity expansion in Belfast and continued to invest in research and development, including its Mammalian Antibody Library. The company reported a full-year revenue of #2.2m and a loss of #1.3m, while maintaining a strong cash position of #2.0m to support future growth.
Company: Fusion Antibodies PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2019
Type: AR2
Pages: 60
Back to company
Fusion Antibodies PLC
Annual Report And Accounts
The report outlines Fusion Antibodies plc's financial and operational performance for the fiscal year ended March 31, 2019. Despite a challenging first half, the company achieved record revenues in the second half, driven by its humanisation services and the introduction of the Rational Affinity Maturation Platform (RAMP™). Fusion Antibodies completed its laboratory capacity expansion in Belfast and continued to invest in research and development, including its Mammalian Antibody Library. The company reported a full-year revenue of #2.2m and a loss of #1.3m, while maintaining a strong cash position of #2.0m to support future growth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees